Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Brogidirsen in Duchenne Muscular Dystrophy
NCT05135663Phase 2Active, not recruiting
- Sponsor
- Nippon Shinyaku
- Start
- Jun 2021
- Primary completion
- Apr 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of brogidirsen in Duchenne muscular dystrophy (DMD), sponsored by Nippon Shinyaku. Started Jun 2021; status: active, not recruiting.
02
Drugs
brogidirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05135663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135663.